Advaxis, Inc. (ADXS)

Teaching the Immune System to Fight Cancer™

The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.

Clinical Pipeline

Clinical Pipeline

Visit Advaxis Clinical Pipeline for more information on ADXS-HPV Clinical Program for HPV-associated cancers.

View Clinical Pipeline

Industry Recognition

Scientific Publications

Advaxis was awarded “Best Early-Stage Biotech” and “Best Financing Deal” at the Vaccine Industry Excellence (ViE) Awards 2015, held at the 15th World Vaccine Congress in Washington, D.C. on April 8, 2015.

Learn More

Investors

More Information

Upcoming Event

Business Update Conference Call